Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Synthetic polymer or copolymer
Reexamination Certificate
2007-10-09
2007-10-09
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Synthetic polymer or copolymer
C424S278100, C424S810000, C514S002600, C514S012200, C530S806000
Reexamination Certificate
active
09768872
ABSTRACT:
The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 4594409 (1974-11-01), Hayashi et al.
patent: 3991210 (1976-11-01), Shea
patent: 4129666 (1978-12-01), Wizerkaniuk
patent: 4339431 (1982-07-01), Gaffar
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5554372 (1996-09-01), Hunter et al.
patent: 5583031 (1996-12-01), Stern
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 5623052 (1997-04-01), McLean et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5668117 (1997-09-01), Shapiro et al.
patent: 5719296 (1998-02-01), Acton, III et al.
patent: 5734023 (1998-03-01), Bishwajit et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5886156 (1999-03-01), McLean et al.
patent: 5958972 (1999-09-01), Hupe et al.
patent: 5965600 (1999-10-01), Sato et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6162800 (2000-12-01), Dolle et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Kontino et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6800285 (2004-10-01), Rodriguez et al.
patent: 6800287 (2004-10-01), Gad et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 7022663 (2006-04-01), Gilbert et al.
patent: 7033582 (2006-04-01), Yong et al.
patent: 7074580 (2006-07-01), Gad et al.
patent: 2001/0055568 (2001-12-01), Gilbert et al.
patent: 2002/0037848 (2002-03-01), Einsenbach-Schartz et al.
patent: 2002/0055466 (2002-05-01), Aharoni et al.
patent: 2002/0077278 (2002-06-01), Yong et al.
patent: 2002/0107388 (2002-08-01), Vandenbark
patent: 2003/0170729 (2003-09-01), Klinger
patent: 2004/0006022 (2004-01-01), Strominger et al.
patent: 2005/0019322 (2005-01-01), Rodriguez et al.
patent: 2005/0170004 (2005-08-01), Rosenberger
patent: 2005/0171286 (2005-08-01), Kinfino et al.
patent: 2005/0256046 (2005-11-01), Gad et al.
patent: 2006/0052586 (2006-03-01), Dolitzky
patent: 2006/0122113 (2006-06-01), Pinchasi et al.
patent: 3930733 (1991-03-01), None
patent: 0378246 (1990-06-01), None
patent: 0383620 (1990-08-01), None
patent: 0359783 (1995-11-01), None
patent: WO9533475 (1995-12-01), None
patent: 1292279 (2003-03-01), None
patent: 254996 (1996-08-01), None
patent: 1690368 (1995-08-01), None
patent: 1469826 (1995-11-01), None
patent: 451182051 (1985-09-01), None
patent: 461664845 (1991-07-01), None
patent: WO8810120 (1988-12-01), None
patent: WO9202543 (1992-02-01), None
patent: WO9403484 (1994-02-01), None
patent: WO9426774 (1994-11-01), None
patent: WO9526980 (1995-10-01), None
patent: WO9531990 (1995-11-01), None
patent: WO9531997 (1995-11-01), None
patent: WO9830227 (1998-07-01), None
patent: WO0005249 (2000-02-01), None
patent: WO0005250 (2000-02-01), None
patent: WO0018794 (2000-04-01), None
patent: WO0020010 (2000-04-01), None
patent: WO0027417 (2000-05-01), None
patent: WO0152878 (2001-07-01), None
patent: WO0160392 (2001-08-01), None
patent: 01085797 (2001-11-01), None
patent: WO0193828 (2001-12-01), None
patent: WO0193893 (2001-12-01), None
patent: WO0197846 (2001-12-01), None
patent: 02076503 (2002-10-01), None
patent: 03048735 (2003-06-01), None
patent: 44980214 (1999-09-01), None
Tisch, R et al. Proc. Nat. Acad. Sci. (USA). 1994. 91:437-438.
Teitelbaum, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide”,Eur. J. Immunol., 1971, 1, 242-248.
Teitelbaum, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide”,Israel J. Med. Sci., 1971, 7, 630-631 (Abstract).
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen”,Israel J. Med. Sci., 1972, 8, 1759-1760.
Teitelbaum, et al., “Protection Against Experimental Allergic Encephalomyelitis”,Nature, 1972, 240, 564-566.
Webb, et al., “Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer”,Israel J. Med. Sci., 1972, 8, 656-657.
Teitelbaum, et al., “Suppression of Experimental Allergic Encephalomyelitis with Basic Polymers”,Eur. J. Immunol., 1973, 3, 273-279.
Webb, et al., “In Vivo and in Vitro Immunological Cross-reactions between Basic Encephalitogen and Synthetic Basic Polypeptides Capable of Suppressing Experimental Allergic Encephalomyelitis”,Eur. J. Immunol., 1973, 3, 279-286.
Teitelbaum, et al., “Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1”,Israel J. Med. Sci., 1974, 10(9), 1172-1173.
U.S. Appl. No. 09/359,099, filed Jul. 22, 1999, Strominger et al.
U.S. Appl. No. 09/405,743, filed Sep. 24, 1999, Gad et al.
U.S. Appl. No. 09/816,989, filed Mar. 23, 2001, Gad et al.
U.S. Appl. No. 09/875,429, filed Jun. 5, 2001, Yong and Chabot.
U.S. Appl. No. 09/885,227, filed Jun. 20, 2001, Rodriquez and Ure.
Teitelbaum, et al., “Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer”,Clin. Immunol. Immunopath., 1974, 3, 256-262.
Webb, et al., “Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer”,Isr. J. Med. Sci., 1975, 11, 1388 (Abstract).
Webb, et al., “Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids”,Immunochem., 1976, 13, 333-337.
Abramsky, et al., “Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis”,J. Neurol. Sci., 1977, 31, 433-438.
Teitelbaum, et al., “Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1”,Israel J. Med. Sci., 1977, 13, 1038 (Abstract).
Arnon, et al., “Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids”,Neurol., 1978, 28, 336 (Abstract).
Sela, et al., “Experimental Allergic Encephalomyelitis in”Menarini Series on Immunopathology, vol. 1,First Symposium of Organ Specific Autoimmunity, Cremona, Italy, Jun. 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21.
Alvord, et al., “Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys”,Ann. Neurol., 1979, 6, 469-473.
Keith, et al., “The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs”J. Neurol. Sci., 1979, 42, 267-274.
Lando, et al., “Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE”,J. Immunol., 1979, 123, 2156-2160. (Abstract).
Lando et al., “Experimental Allergic Encephalomyelitis in Mice—Suppression and Prevention with COP-1”,Israel J. Med. Sci., 1979, 15, 868-896 (Abstract).
Teitelbaum, et al., “Blocking of Sensitization to Encephalitogenic Basic Proteins in Vitro by Synthetic Basic Copolymer (COP 1)” inCell Biology and Immunology of Leukocyte Function(Academic Press, New York, 1979) 681-685.
Teitelbaum, “Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer—Relevance to Multiple Sclerosis”, inHumoral Immunity in Neurological Diseases(Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613.
Arnon, et al., “Desensitization of Experimental Allergic Enceph
Aharoni Rina
Arnon Ruth
Fridkis-Hareli Masha
Sela Michael
Strominger Jack L.
Chan Christina
President and Fellows of Harvard College
VanderVegt F. Pierre
White John P.
Yeda Research and Development Co. Ltd.
LandOfFree
Treatment of autoimmune conditions with copolymer 1 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of autoimmune conditions with copolymer 1 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of autoimmune conditions with copolymer 1 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3844584